Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The presynaptic neuromuscular junction is the terminal end of a motor neuron axon that forms a synapse with a skeletal muscle fiber. Its primary function is to release acetylcholine (ACh) into the synaptic cleft upon arrival of an action potential. This release is dependent on calcium influx, which triggers the fusion of ACh-containing vesicles with the presynaptic membrane. The released ACh then diffuses across the synaptic cleft and binds to nicotinic acetylcholine receptors on the muscle fiber, initiating muscle contraction. Dysregulation of presynaptic function can lead to neuromuscular disorders and is a target for various drugs and toxins.
Drugs act by modulating acetylcholine release, calcium influx, or vesicle fusion at the presynaptic terminal.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Presynaptic Neuromuscular Junction (Presynaptic NMJ).